“仁捷生物”產品文獻：Clinical Value of Asymmetrical Dimethylarginine Detection in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension

-----------------------------------------------------------------------------------------------------------------------

Juan Liu , Qiang Fu, Lili Jiang, and Youlian Wang

Department of Rheumatology, Jiangxi Provincial People’s Hospital, Nanchang 330006, China

Correspondence should be addressed to Youlian Wang; 

Received 4 April 2019; Revised 29 May 2019; Accepted 27 July 2019; Published 14 August 2019

Guest Editor: Yan Yang

Copyright © 2019 Juan Liu et al.-is is an open access article distributed under the Creative Commons Attribution License, which

permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To evaluate the clinical value of serum asymmetrical dimethylarginine (ADMA) in patients with connective tissue

disease- (CTD-) associated pulmonary arterial hypertension (PAH). Methods. 88 patients with CTD were recruited between

December 2017 and August 2018 in Jiangxi Provincial People’s Hospital. Patients were further divided into two groups: CTD

without PAH (n = 45 cases) and CTD-with PAH (n = 43 cases), according to the pulmonary systolic blood pressure measured by

echocardiography. 40 healthy controls were also included (n =40 cases). -e clinical data, including laboratory examinations,

echocardiographic measurements, pulmonary function, and serum ADMA levels determined by enzyme-linked immunosorbent

assay, (ELISA) were collected. -e correlation between ADMA levels and the occurrence of PAH, pulmonary function, and other

laboratory indexes in CTD patients were analyzed. Statistical analyses were performed by SPSS (version 23); P < 0.05 was

considered statistically signifificant. Results. -e serum levels of ADMA in the CTD-PAH group were signifificantly higher than

those of the CTD-without PAH group and healthy control group (P < 0.05); the serum ADMA levels were (0.706 ± 0.153 μmol/L),

(1.015 ± 0.122 μmol/L), and (0.661 ± 0.113 μmol/L), respectively. -ere was no signifificant difffference between the CTD-without

PAH group and healthy control group (P < 0.05). Correlation analysis showed that serum ADMA levels were positively correlated

with sPAP and NT-proBNP and negatively correlated with DLCO% (r =0.802, 0.475, 0.585, P < 0.001). M*riate analysis

indicated that elevated serum ADMA levels increased the risk for the appearance of PAH in CTD patients (OR =57.460,

P < 0.001). Using the receiver operating characteristic (ROC) curve analysis, at the cutoffff level of 0.810 μmol/L, ADMA showed

good diagnostic effiffifficacy as follows: sensitivity was 97.7%, specifificity was 75.6%, and the area under the curve (AUC) was 0.947

(P < 0.001). Conclusion. Increased ADMA levels are independently associated with the presence and severity of PAH in CTD

patients. -e levels of ADMA in the serum may contribute to be a noninvasive indicator for early diagnosis of CTD-with PAH patients.

Blood samples for measurement of serum ADMA concentrations were naturally coagulated at room temperature for 20 minutes and centrifuged for about 20 minutes (3000 rpm), and the supernatants were stored in 1 mL aliquots at −80°C until further use. Concentration of ADMA was measured in serum samples by using an enzyme immunoassay ELISA kit provided by Shanghai Renjie Biotechnology Co., Ltd. The whole detection process was completed in strict accordance with the operating instructions. The absorbance (OD) was measured at 450 nm by using a Microplate reader, and each sample was duplicated.

ELISA試劑盒：人不對稱二甲基精氨酸（ADMA）ELISA試劑盒 

產品貨號：RJ11983